AA amyloidosis in inflammatory active malignant paraganglioma

Amyloid. 2022 Jun;29(2):137-138. doi: 10.1080/13506129.2021.2016691. Epub 2022 Feb 2.

Authors

Sandra Ihne^{1

2}, Malte Kircher³, Aikaterini Papagianni^{1

2}, Oliver Goetze^{1

2}, Caroline Morbach^{1

2}, Rudolf A Werner², Daniel Zeller^{1

2}, Claudia Sommer^{1

2}, Andreas Rosenwald², Kerstin Amann⁴, Reinhold P Linke⁵, Constantin Lapa³, Hermann Einsele^{1

2}, Andreas Geier^{1

2}, Laura Obici⁶, Giovanni Palladini⁶, Stefan Knop^{1

2}, Stefan Störk^{1

2}

Affiliations

¹ Interdisciplinary Amyloidosis Center of Northern Bavaria, Würzburg, Germany.
² University and University Hospital Würzburg, Würzburg, Germany.
³ Nuclear Medicine, Medical Faculty, University of Augsburg, Augsburg, Germany.
⁴ Department of Nephropathology, University Erlangen, Erlangen, Germany.
⁵ Reference Center of Amyloid Diseases, Munich, Germany.
⁶ Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

PMID: 35107388
DOI: 10.1080/13506129.2021.2016691

No abstract available

Keywords: 18F-Florbetaben-PET/CT; AA amyloidosis; amyloid; response assessment.

MeSH terms

Amyloidosis* / complications
Amyloidosis* / diagnosis
Humans
Paraganglioma* / complications
Serum Amyloid A Protein

Substances

Serum Amyloid A Protein

Supplementary concepts

AA amyloidosis